Intravacc

Intravacc B.V. operates as a specialized Contract Development and Manufacturing Organization (CDMO) in the global vaccine market, positioned to bridge the gap between academic research and large-scale pharmaceutical production. The company's lineage traces back to the Dutch Bacteric Therapeutic Institute, founded in 1894, evolving through various national health institutions before Intravacc was established in 2013 as the research and development arm of the privatized Netherlands Vaccine Institute (NVI). It became a state-owned holding company in 2021 and was subsequently acquired by the investment group First Dutch in early 2024, a move intended to strengthen its market position while keeping its headquarters in the Netherlands.

The company is led by CEO Dr. Jan Groen, a virologist with extensive experience in the biotechnology and pharmaceutical sectors, including leadership roles at MDxHealth, Agendia, and Focus Diagnostics. His background in clinical diagnostics and commercializing FDA-cleared products aligns with Intravacc's mission to translate vaccine concepts into viable clinical candidates.

Intravacc's business model is a hybrid approach. The majority of its revenue, projected at 70-80%, is generated from CDMO services for a diverse clientele that includes biotech firms, major pharmaceutical companies, non-governmental organizations (NGOs), and governmental agencies like the NIH and CEPI. These services encompass the entire vaccine development trajectory, from concept and process development to pilot production for Phase I/II clinical trials. The remaining 20-30% of its business focuses on developing and out-licensing its proprietary pipeline of vaccine candidates, particularly those administered intranasally.

Central to its operations are four proprietary technology platforms designed to streamline vaccine development. The OMV-Vacc® platform utilizes Outer Membrane Vesicles from gram-negative bacteria to create vaccines against bacterial, viral, and parasitic infections, as well as for oncology. Its Cell-Vacc® technology employs a Vero cell line for the large-scale production of viral vaccines. The Con-Vacc® and E.co-Vacc® platforms are used for developing conjugate vaccines and leveraging E. coli for recombinant protein expression, respectively. Notably, the company's know-how has contributed to approximately 30% of all childhood vaccines, including those for polio, measles, and influenza.

Keywords: vaccine development, CDMO, translational vaccinology, contract development manufacturing, infectious diseases, therapeutic vaccines, intranasal vaccines, OMV platform, Vero cells, vaccine technology, clinical trials, GMP production, immunotherapy, public-private partnerships, biopharmaceutical, viral vaccines, bacterial vaccines, oncology vaccines, biologics manufacturing, process development